Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Entera Bio Ltd.NASDAQ: ENTX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $3.51M (cash outflow) rose 36.5% year over year, ahead of the +22.7% change in trailing-twelve-month net income. Sequentially, it rose 16.2% from the prior quarter. Over 3 fiscal years it compounded at -4.3% a year.
Context
- Net income amounted to 27235.7% of revenue in FY2025, up 21964.4 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$22.98M (+100.9%) for the fiscal year ending Dec 2026, a step up from the +19.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.51M+16.2% QoQ
- Last fiscal yearDec 2025
- -$11.44M+19.9% YoY
- LTMMar 2026
- -$12.38M+22.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +36.5% | +52.0% | +15.4 pp |
| 1 year | +19.9% | +100.9% | +81.0 pp |
| 3-year CAGR | -4.3% | +17.1% | +21.4 pp |
| 5-year CAGR | +12.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (11.44M) USD
- Year-over-year change
- -19.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.44M) | -19.9% |
| FY2024 | 2024-12-31 | (9.54M) | -7.3% |
| FY2023 | 2023-12-31 | (8.89M) | +32.0% |
| FY2022 | 2022-12-31 | (13.07M) | -7.3% |
| FY2021 | 2021-12-31 | (12.19M) | — |
Net Income vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's LTM Mar 2026 net income of $12.38M is the 9th largest of the 10 companies compared; the peer median is $46.9M.
- Its year-over-year change of +22.7% is the 4th highest of 9, against a peer median of -7.3%.
- Over three fiscal years its annual growth of -4.3% compares with a peer median of -3.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $113.28M | -2.6% | +41.5% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $106.93M | +82.4% | — | 892.4% |
| LTM Mar 2026 | $84.93M | -12.0% | -32.8% | — | |
| LTM Mar 2026 | $70.49M | -17.9% | -7.5% | 468.7% | |
| LTM Mar 2026 | $62.51M | +132.2% | +0.2% | 50.5% | |
| LTM Mar 2026 | $46.9M | -164.3% | — | 4088.8% | |
| LTM Mar 2026 | $30.92M | — | +47.5% | — | |
| LTM Mar 2026 | $15.24M | +121.8% | — | 27.8% | |
| LTM Mar 2026 | $12.38M | +22.7% | -4.3% | — | |
| LTM Apr 2026 | $10.1M | -17.6% | -7.1% | — | |
| Peer median (excluding ENTX) | $46.9M | -7.3% | -3.5% | 468.7% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.19M) | (13.07M) | (8.89M) | (9.54M) | (11.44M) |
| Depreciation & Amortization | 53K | 64K | 56K | 46K | 30K |
| Deferred Income Tax | (217K) | 174K | 29K | 14K | 0 |
| Stock-Based Compensation | 1.86M | 2.25M | 1.69M | 2.56M | 2.75M |
| Change in Working Capital | 1.41M | (1.84M) | (195K) | 112K | 1.26M |
| Accounts Receivables | 72K | (63K) | 246K | (126K) | 126K |
| Inventory | (72K) | 0 | 0 | 0 | 0 |
| Accounts Payables | 74K | (149K) | 66K | 49K | 316K |
| Other Working Capital | 1.34M | (1.62M) | (507K) | 189K | 815K |
| Other Non-Cash Items | 18K | (78K) | 1.69M | (5K) | 32K |
| Operating Cash Flow | (9.06M) | (12.5M) | (7.31M) | (6.82M) | (7.37M) |
| Capital Expenditures | (17K) | (47K) | (17K) | (3K) | (107K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (55K) | 0 | 0 | 0 |
| Investing Cash Flow | (17K) | (102K) | (17K) | (3K) | (107K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 21.81M | 13K | 6.62M | 3.96M | 13.71M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.58M | 0 | (580K) | 516K | 0 |
| Financing Cash Flow | 25.38M | 13K | 6.04M | 4.48M | 13.71M |
| Effect of Forex Changes | 0 | 5K | 0 | 0 | (10K) |
| Net Change in Cash | 16.3M | (12.58M) | (1.29M) | (2.35M) | 6.23M |
| Free Cash Flow | (9.08M) | (12.55M) | (7.33M) | (6.82M) | (7.48M) |
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.